Biodexa Pharmaceuticals Plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BDRX Nasdaq 2834 www.biodexapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biodexa Pharmaceuticals Plc

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer - Jan 22nd, 2025 1:30 pm
Result of General Meeting - Nov 22nd, 2024 1:30 pm
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic - Nov 21st, 2024 12:35 pm
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq - Nov 12th, 2024 1:48 pm
Notice of General Meeting - Nov 7th, 2024 9:30 pm
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - Oct 17th, 2024 11:30 am
Biodexa Announces Successful Appeal of Nasdaq Delisting - Oct 15th, 2024 8:15 pm
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - Oct 4th, 2024 12:30 pm
Interim results for the six months ended June 30, 2024 - Sep 26th, 2024 12:30 pm
ADR Ratio Change - Sep 19th, 2024 8:30 pm
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant - Sep 16th, 2024 12:30 pm
Receipt of Nasdaq Delisting Determination - Plans to Appeal - Aug 30th, 2024 8:30 pm
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement - Jul 23rd, 2024 12:30 pm
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement - Jul 19th, 2024 12:30 pm
Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada - Jul 16th, 2024 12:30 pm
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data - Jul 11th, 2024 12:30 pm
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 - Jul 2nd, 2024 12:30 pm
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) - Jun 24th, 2024 12:30 pm
Results of Annual General Meeting - Jun 13th, 2024 1:35 pm
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona - Jun 10th, 2024 12:30 pm